Product with eye protection function

Abstract

The invention provides a product with an eye protection function, and belongs to the technical field of eye health. The invention provides application of components of aronia melanocarpa fruits in preparation of eye protection products. The aronia melanocarpa fruit extract is found to have a protection effect on eye cell apoptosis, retinal injury and the like, for example, the aronia melanocarpa fruit extract has an eye protection effect of resisting eye blue light injury, remarkably improves retina cell apoptosis caused by illumination and meanwhile reduces the in-vivo lipid peroxidation level and the in-vivo inflammation level. Based on the eye protection effect of the aronia melanocarpa fruit extract, the invention develops drugs for preventing and treating retinal light injury diseases and relieving disease symptoms, develops health-care foods with functions of relieving visual fatigue and the like, and also develops common foods containing the aronia melanocarpa fruits.

Description

Technical Field

[0001] The invention belongs to the technical field of eye health, and in particular relates to a product with eye protection purpose. Background Art

[0002] The "14th Five-Year Plan for National Eye Health" issued by the National Health Commission proposes to continue to promote the high-quality development of my country's eye health and further improve the eye health level of the people. Eye health is an important part of national health, involving people of all ages throughout their life. However, as electronic products gradually penetrate into people's lives, excessive use of eyes has become the norm, troubling people from children to the elderly. Myopia problems in children and adolescents, high blue light exposure problems in young and middle-aged people, and macular degeneration problems in the elderly are all related to varying degrees of retinal light damage. In particular, age-related macular degeneration (AMD) is a difficult-to-treat disease that seriously damages vision and is one of the leading causes of blindness in adults over 50 years old worldwide. With the aging of the population, the incidence of AMD is also increasing year by year. It is estimated that the number of AMD patients worldwide will reach 288 million by 2040, and there is currently no drug treatment with obvious efficacy except for anti-VEGF drugs in clinical practice. It can be seen that related retinal diseases and even visual impairment caused by retinal light damage have a very serious impact on the physical and mental health and quality of life of the people, and increase the burden on families and society. Therefore, preventing retinal light damage and promoting visual health have become important issues that need to be urgently addressed in the Healthy China strategy. Summary of the invention

[0003] The invention provides a product with eye protection purpose, and the aronia nigra fruit has a significant eye protection effect.

[0004] The invention provides application of components of Aronia nigra fruit in preparing eye protection products.

[0005] Preferably, the components of the Aronia nigra berries include an extract of Aronia nigra berries or a product made from the juice of Aronia nigra berries.

[0006] Preferably, the extract of Aronia nigra fruit comprises an Aronia nigra fruit water extract obtained using water as a solvent;

[0007] The product made from the juice of Aronia nigra fruit includes juice powder prepared by squeezing the juice of Aronia nigra fruit.

[0008] Preferably, the eye protection product includes at least one of the following functions: (1) treating and / or preventing eye diseases associated with retinal light damage;

[0009] (2) Treat and / or alleviate ocular symptoms associated with retinal photodamage;

[0010] (3) Alleviate visual fatigue.

[0011] Preferably, the types of the eye care products include at least one of the following: drugs, foods, and medical device products.

[0012] The present invention provides a drug related to the prevention and / or treatment of eye diseases associated with retinal light damage, comprising an active ingredient and a pharmaceutically acceptable excipient;

[0013] The active ingredient includes the components of Aronia melanocarpa fruit.

[0014] Preferably, when the active ingredient of the drug includes the aqueous extract of Aronia melanocarpa fruit, the working concentration of the aqueous extract of Aronia melanocarpa fruit is not less than 87.5 μg / ml.

[0015] The present invention provides a health food for alleviating visual fatigue, and the active ingredient includes the components of Aronia melanocarpa fruit;

[0016] The components of Aronia melanocarpa fruit include the extract of Aronia melanocarpa fruit or a product made from the juice of Aronia melanocarpa fruit.

[0017] Preferably, the dosage forms of the health food include at least one of the following: ointment, powder, liquid, tablet, gel, capsule, and granule.

[0018] The present invention provides a common food containing the components of Aronia melanocarpa fruit.

[0019] Beneficial effects: The present invention provides the application of the components of Aronia melanocarpa fruit in the preparation of eye care products. In the examples, by constructing a zebrafish blue light eye injury model and a mouse retinal light injury model, and treating the two animal models with the extract of Aronia melanocarpa fruit, it is found that the extract of Aronia melanocarpa fruit has a protective effect on ocular cell apoptosis, retinal injury, etc. The present invention first proposes that the extract of Aronia melanocarpa fruit has a protective effect on retinal light injury. For example, the extract of Aronia melanocarpa fruit has the eye care effect of resisting ocular blue light injury and significantly improving the apoptosis of retinal cells caused by light, while reducing the in vivo lipid peroxidation level and in vivo inflammation level, proving that the extract of Aronia melanocarpa fruit has a protective effect on cell oxidative stress injury and a protective effect on cell inflammatory response. Based on the eye care effect of the extract of Aronia melanocarpa fruit, the present invention develops drugs for preventing, treating retinal light injury diseases and alleviating disease symptoms, develops health foods with functions such as alleviating visual fatigue, and common foods containing the above-mentioned Aronia melanocarpa fruit. Description of the Drawings

[0020] Figure 1It is a typical diagram of the fluorescence intensity of apoptotic cells in the eyes of zebrafish after treatment with Aronia melanocarpa fruit extract and lutein. The green fluorescent particles indicated by the yellow arrows in the figure are apoptotic cells;

[0021] Figure 2 It is a quantitative diagram of the fluorescence intensity of apoptotic cells in the eyes of zebrafish after treatment with Aronia melanocarpa fruit extract and lutein;

[0022] Figure 3 It is a H&E staining diagram of mouse retina. In the figure, A is the H&E staining diagram of mouse retina tissue and the thickness diagrams of the outer nuclear layer and inner nuclear layer of the retina, scale bar: 20μm; B and C are the quantitative diagrams of the thickness of the outer nuclear layer and inner nuclear layer of the retina, number of mice (n = 5 - 6);

[0023] Figure 4 It is a TUNEL staining diagram of apoptotic cells in mouse retina. In the figure, A is the TUNEL fluorescence staining diagram of mouse retina, DAPI blue fluorescence represents the nucleus, and TUNEL red fluorescence represents apoptotic cells, scale bar: 500μm and 100μm; B is the quantitative diagram of the fluorescence intensity of apoptotic cells in the retina, number of mice (n = 5 - 6);

[0024] Figure 5 It is a diagram of the content of malondialdehyde in mouse plasma, number of mice (n = 5);

[0025] Figure 6 It is a statistical chart of the expression level of IL-6 in mouse plasma, number of mice (n = 6 - 7). Detailed implementation manners

[0026] The present invention provides the application of the composition of Aronia melanocarpa fruit in the preparation of eye care products.

[0027] The Aronia melanocarpa fruit described in the present invention is the mature fruit on Aronia melanocarpa (Michx.) Elliott. Its composition can include the extract of Aronia melanocarpa fruit or products made from the juice of Aronia melanocarpa fruit in the detailed implementation manners of the present invention. The extract described in the present invention is water extraction in a specific embodiment, which can be self-extracted, and the extraction method can be carried out by using the conventional water extraction method in the art; it can also be purchased, and in the embodiment, it is purchased from Daxing'anling Lingbei Cold Zone Biotechnology Co., Ltd. The products made from the juice of Aronia melanocarpa fruit described in the present invention include juice powder prepared by juicing Aronia melanocarpa fruit, such as juice powder prepared after a series of processes of juicing, filtering, concentrating, spraying, and drying Aronia melanocarpa fruit.

[0028] In the embodiments of the present invention, by constructing a zebrafish blue light eye injury model and a mouse retinal light injury model, and treating the two animal models with the extract of Aronia melanocarpa fruit, it is found that the extract of Aronia melanocarpa fruit has a protective effect on ocular cell apoptosis, retinal injury, etc. Therefore, the eye care product of the present invention includes at least one of the following functions: (1) treating and / or preventing eye diseases related to retinal light injury;

[0029] (2) treating and / or relieving eye symptoms related to retinal light injury;

[0030] (3) relieving visual fatigue.

[0031] The eye diseases related to retinal light injury described in the present invention may be acute retinal light injury, age-related macular degeneration, retinal macular hole, blurred vision or visual fatigue caused by chronic light injury, etc.; the eye symptoms related to retinal light injury may be: reducing the apoptosis of ocular cells caused by light injury such as blue light injury; improving the morphological changes of the outer nuclear layer of the retina caused by light injury and increasing the thickness of the outer nuclear layer and the inner nuclear layer; reducing the level of lipid peroxidation in the body caused by light exposure and having a protective effect on cell oxidative stress injury; significantly reducing the level of inflammation in the body caused by light exposure and having a protective effect on cell inflammatory response.

[0032] The present invention does not particularly limit the type of the eye care product, which may be at least any one of drugs, foods and medical device products.

[0033] The present invention provides a drug related to the prevention and / or treatment of eye diseases related to retinal light injury, including an active ingredient and a pharmaceutically acceptable excipient;

[0034] The active ingredient includes the components of Aronia melanocarpa fruit.

[0035] In some embodiments of the present invention, when the active ingredient of the drug includes the water extract of Aronia melanocarpa fruit, the working concentration of the water extract of Aronia melanocarpa fruit is not less than 87.5 μg / ml. The present invention does not particularly limit the dosage form of the drug, which may be an external dosage form or an oral dosage form. The external dosage forms include paste, gel, liquid eye drops, etc., and the oral dosage forms include tablets, capsules, granules, etc.; and there is no particular limitation on the preparation method of the drug. It can be prepared by mixing based on the dosage form and pharmaceutically acceptable excipients using conventional methods in the art.

[0036] The present invention provides a health food for relieving visual fatigue, and the active ingredient includes the components of Aronia melanocarpa fruit;

[0037] The composition components of the black chokeberry fruits include the extract of black chokeberry fruits or products made from the juice of black chokeberry fruits.

[0038] The present invention does not particularly limit the dosage form of the health food, which may be at least one of the following: ointment, powder, liquid, tablet, gel, capsule, and granule.

[0039] The present invention provides a common food containing the composition components of black chokeberry fruits.

[0040] The present invention does not particularly limit the type of the common food. For example, it may be gummy candies, compressed candies, solid beverages, liquid beverages, dairy products, etc., as well as common foods with the composition components of black chokeberry fruits added in the ingredient list.

[0041] In order to further illustrate the present invention, the following describes in detail a product with eye protection use provided by the present invention in combination with embodiments, but they cannot be understood as limiting the protection scope of the present invention.

[0042] The drugs and reagents used in the embodiments of the present invention, unless otherwise specified, are all routinely purchased in the art:

[0043] The black chokeberry fruit extract (aqueous extract) was purchased from Daxing'anling Lingbei Cold Zone Biotechnology Co., Ltd.

[0044] Using ultrapure water as the solvent, the above-mentioned black chokeberry fruit extract was dissolved and formulated into aqueous solutions with final concentrations of 87.5 and 175 μg / mL for zebrafish experiments;

[0045] In the zebrafish experiment, lutein (batch number A2316085) purchased from Shanghai Aladdin Biochemical Technology Co., Ltd. was used as the positive drug, and it was formulated with DMSO as the solvent. The dosage of zebrafish was 62.5 μg / mL;

[0046] In the mouse experiment, using sodium carboxymethylcellulose (CMC-Na) as the solvent, the above-mentioned black chokeberry fruit extract was formulated into a suspension and gavaged to mice. The dosage of mice was 100 and 200 mg of the freeze-dried extract / kg; lutein (batch number A1600) purchased from Chengdu Mansite Biotechnology Co., Ltd. was used as the positive drug, and it was prepared into a suspension with CMC-Na and gavaged to mice, with a dosage of 100 mg of lutein powder / kg.

[0047] Example 1

[0048] This experiment was commissioned to Hangzhou Huante Biotechnology Co., Ltd. to complete the construction and subsequent processing of zebrafish models (Project No.: 9037). The data was statistically analyzed using SPSS 26.0 software, ***P<0.001; #P<0.05; P<0.001. * indicates the statistical difference between the model group and the normal control group, and # indicates the statistical difference between different drug administration groups and the model group.

[0049] 1.1 Experimental animals

[0050] Zebrafish were all raised in fish culture water at 28°C (Water quality: Add 200 mg of instant sea salt to every 1 L of reverse osmosis water, the conductivity is 450 - 550 μS / cm; pH is 6.5 - 8.5; hardness is 50 - 100 mg / L CaCO3). They were provided by the fish culture center of Huante Biotechnology Co., Ltd. The license number for the use of experimental animals is: SYXK(Zhe)2022 - 0004. The feeding management meets the requirements of international AAALAC accreditation (Accreditation No.: 001458), and the IACUC ethical review number is: IACUC - 2024 - 9037 - 01.

[0051] 1.2 Instruments, consumables and reagents

[0052] Dissecting microscope (SZX7, OLYMPUS, Japan); CCD camera (VertA1, Shanghai Tusen Vision Technology Co., Ltd., China); Precision electronic balance (CP214, OHAUS, USA); Ultra - pure water machine (EPED - S2 - 30D, Nanjing EPE Technology Co., Ltd., China); Blue light instrument (50w450nm, China); Biochemical incubator (SPX - 250B - Z, Shanghai Boxun Medical Biotechnology Co., Ltd., China); Electric focusing continuously variable magnification fluorescence microscope (AZ100, Nikon, Japan); 6 - well plate (Batch No. DB1000305, Zhejiang Beilanbo Biotechnology Co., Ltd., China); 0.22 μM disposable needle filter (Batch No. 23214867, Biosharp, China).

[0053] Streptomyces protease E (Batch No. G12511Y118034, Shanghai Yuanye Biotechnology Co., Ltd., China); Dimethyl sulfoxide (DMSO, Batch No. BCCD8942, Sigma, Switzerland); Methyl cellulose (Batch No. C2004046, Shanghai Aladdin Biochemical Technology Co., Ltd., China); Acridine orange (AO, Batch No. C12894919, Shanghai Macklin Biochemical Co., Ltd., China); Lutein (Batch No. A2316085, Shanghai Aladdin Biochemical Technology Co., Ltd., China).

[0054] 1.3 Determination of the maximum test concentration (MTC)

[0055] Wild-type AB strain zebrafish at 1 day post-fertilization (1 dpf) were randomly selected after hatching and irradiated with blue light to establish a zebrafish blue light eye injury model. At 3 dpf, model zebrafish with good developmental status were randomly selected and allocated into 6-well plates, with 30 zebrafish in each well (experimental group). Different concentrations of Aronia melanocarpa fruit extract were dissolved in water and administered (the concentrations are shown in Table 1). At the same time, a normal control group and a model group were set up, and the volume of each well was 3 mL. After treatment at 28 °C for 1 day, the MTC of Aronia melanocarpa fruit extract on the model zebrafish was measured.

[0056] Under the conditions of this experiment, the MTC of Aronia melanocarpa fruit extract against blue light eye protection in zebrafish was 350 μg / mL (Table 1). In subsequent blue light eye protection efficacy experiments, two doses of Aronia melanocarpa fruit extract, 87.5 and 175 μg / mL, were used.

[0057] Table 1 Results of the experiment on exploring the concentration of Aronia melanocarpa fruit extract for blue light eye protection efficacy (n = 30)

[0058]

[0059] 1.4 Evaluation of blue light eye protection efficacy

[0060] Wild-type AB strain zebrafish at 1 dpf were randomly selected after hatching and irradiated with blue light to establish a zebrafish blue light eye injury model. At 3 dpf, model zebrafish with good developmental status were randomly selected and allocated into 6-well plates, with 30 zebrafish in each well (experimental group). Different concentrations of Aronia melanocarpa fruit extract were dissolved in water and administered (the concentrations are shown in Table 2), and the positive control lutein was at a concentration of 62.5 μg / mL. At the same time, a normal control group and a model group were set up, and the volume of each well was 3 mL. After treatment at 28 °C for 1 day, the zebrafish in each experimental group were stained with AO in the dark for 30 min. After washing 3 times with standard dilution water, 10 zebrafish were randomly selected from each experimental group and placed under a fluorescence microscope for photographing. The Image J software was used to analyze and collect data, and the fluorescence intensity of apoptotic cells in the zebrafish eyes was analyzed and statistically counted. The blue light eye protection efficacy of Aronia melanocarpa fruit extract was evaluated based on the statistical analysis results of the above indicators. The statistical processing results were expressed as mean ± SE.

[0061] The results are shown in Table 2 and Figures 1-2 as follows. The zebrafish blue light eye injury model showed apoptosis of ocular cells. After treatment with different concentrations of Aronia melanocarpa fruit extract, the apoptosis of ocular cells in zebrafish could be significantly reduced, indicating that Aronia melanocarpa fruit extract has the eye protection effect against blue light-induced eye injury.

[0062] Table 2 Experimental results of evaluating the anti-blue light and eye protection effects of Aronia melanocarpa fruit extract (n = 10)

[0063]

[0064]

[0065] Example 2

[0066] In this example, Prism 8 software was used for statistical chart drawing and statistical analysis. All data were expressed as mean ± standard error. The differences between two groups were analyzed by independent sample t-tests: ****P < 0.0001; ***P < 0.001; **P < 0.01; *P < 0.05; #P < 0.05; ##P < 0.01; P < 0.001; #P < 0.0001. * indicates the statistical difference between the model group and the normal control group, and # indicates the statistical difference between different administration groups and the model group

[0067] 2.1 Experimental animals

[0068] 8-week-old male BALB / c mice were purchased from Zhejiang Vital River Laboratory Animal Technology Co., Ltd. Before the experiment started, all mice were adaptively fed with 12:12 h light / dark in an animal room at a certain temperature and humidity for 1 week, and provided with normal food and drinking water every day. All experimental operations followed the guidelines for animal care and use of the Animal Research Institute of Zhejiang University

[0069] 2.2 Construction of mouse retinal light damage model

[0070] A self-made light box with a length of 108 cm, a width of 50 cm, and a height of 72 cm was used. The light intensity was detected by a light intensity meter to be 8500 - 10000 Lux. After eye examination of the mice, mice with normal eyes were randomly divided into a control group (12 mice), a model group (10 mice), a lutein group (100 mg / kg, 10 mice), a low-dose group of Aronia melanocarpa fruit extract (100 mg / kg, 10 mice), and a high-dose group of Aronia melanocarpa fruit extract (200 mg / kg, 10 mice). Lutein and Aronia melanocarpa fruit extract were suspended in a 5% sodium carboxymethylcellulose (CMC-Na) solution and administered by gavage once a day. Mice in the blank and model groups were gavaged with an equal volume of 5% CMC-Na. The administration was continued for 10 days. After 10 days, the mice in the model group, lutein group, low-dose and high-dose groups of Aronia melanocarpa fruit extract were dark-treated for 36 h, then atropine ophthalmic gel was applied to both eyes of the mice to dilate the pupils, and the mice were placed in a self-made lighting device with a light intensity of 8000 - 10000 Lux (the blank group was raised in a normal environment) for 24 h of continuous light exposure. After the light exposure ended, blood was collected by enucleating the eyeballs of each group of mice, and the eyeball tissues were collected for relevant detections in subsequent experiments.

[0071] 2.3 Main experimental instruments

[0072] The main instruments used in the experiment included a dehydrator, an embedding machine, a pathological slicer, a tissue spreading machine, an oven, glass slides, an upright optical microscope, an imaging system, a light intensity meter, an LED lamp, an electronic balance, an ultra-low temperature refrigerator, a pure water instrument, a shaker, an enzyme label instrument, etc.

[0073] 2.4 Experimental consumables and reagents

[0074] The consumables and reagents required for the experiment included atropine ophthalmic gel, FAS eyeball fixative, PBS buffer, malondialdehyde (MDA) content detection kit, Mouse IL-6 ELISA kit, xylene, differentiating solution, bluing solution, neutral gum, absolute ethanol, environment-friendly dewaxing solution, proteinase K, DAPI dye, anti-fluorescence quenching mounting medium, hematoxylin-eosin (H&E) high-definition constant staining kit, TUNEL kit, etc.

[0075] 2.5 Histopathological detection

[0076] For each group, 5 - 6 mouse eyeball tissues were subjected to H&E staining and apoptotic cell TUNEL fluorescence staining, and the histopathological changes of the mouse eyeball tissues were observed using an optical microscope (completed by Wuhan Sevier Biotechnology Co., Ltd.).

[0077] The retina is the most crucial part of the eye. The inner nuclear layer and the outer nuclear layer of the retina are the main structures of the retina. The outer nuclear layer of the retina is mainly composed of photoreceptor cells, which can receive light stimuli and convert light signals into electrical signals. The inner nuclear layer of the retina contains different types of neuronal cells, which can convert electrical signals into nerve impulses. It can be seen that the cells in the inner / outer nuclear layer of the retina play an important role in the reception and conduction of visual signals. The results of retinal H&E staining are as Figure 3 shown. Light damage caused morphological changes such as loosening and reduced thickness in the outer nuclear layer and the inner nuclear layer of the retinas of mice in the model group, indicating that light caused damage to retinal cells ( Figure 3 in A). Under light conditions, both low-dose and high-dose aronia fruit extracts could well improve the morphological changes in the outer nuclear layer of the retina and increase the thickness of the outer nuclear layer and the inner nuclear layer ( Figure 3 in B-C, Table 3). Moreover, the protective effect of aronia fruit extract on the outer nuclear layer and the inner nuclear layer of the retina was comparable to that of the positive drug lutein, indicating that aronia fruit extract has a good effect on improving retinal light damage.

[0078] The results of TUNEL fluorescence staining of apoptotic cells in retinal tissues are as Figure 4 shown. Light induced a large number of apoptotic retinal cells in mice in the model group (red fluorescence, Figure 4 in A). The high dose of aronia fruit extract could significantly improve the cell apoptosis in the retina caused by light, and the protective effect of aronia fruit extract on retinal light damage was also demonstrated by the TUNEL staining experiment ( Figure 4 in A-B, Table 3).

[0079] Table 3 Effects of lutein and aronia fruit extract on the inner and outer nuclear layers of the retina, the fluorescence intensity of apoptotic eye cells, plasma interleukin 6 (IL-6), and malondialdehyde in mice (mean ± standard deviation)

[0080]

[0081]

[0082] Number of mice (n = 5 - 7). Note: ****P < 0.0001; ***P < 0.001; **P < 0.01; #P < 0.05; ##P < 0.01; P < 0.001; * indicates the statistical difference between the model group and the normal control group, # indicates the statistical difference between different drug administration groups and the model group, and ns indicates no significant difference compared with the model group.

[0083] 2.6 Determination of plasma MDA level in mice

[0084] Collect mouse blood in an anticoagulant tube and centrifuge at 3000 RPM for 10 min at 4°C, then collect the upper plasma. Determine the content of MDA according to the method provided by the kit manufacturer.

[0085] Plasma malondialdehyde (MDA) is one of the main products of cell membrane lipid peroxidation. The content of MDA can be used as an index of lipid peroxidation to reflect the degree of cell membrane lipid peroxidation. The results are as Figure 5 shown in Table 3, indicating that light causes an increase in the level of lipid peroxidation in the model mouse group, while the high dose of Aronia melanocarpa fruit extract can significantly reduce the level of lipid peroxidation in vivo, suggesting its protective effect on cell oxidative stress damage.

[0086] 2.7 Determination of the level of interleukin-6 (IL-6) in mouse plasma

[0087] Take the centrifuged mouse plasma and determine the level of IL-6 according to the method provided by the kit manufacturer. The specific steps are as follows: Transfer various reagents to room temperature and equilibrate for at least 30 min, prepare the reagents according to the method provided by the kit manufacturer and set aside; Set up standard wells and test sample wells respectively, and add 100 μL of standard or serum to each well; Add 50 μL of "detection antibody working solution" to each test well; Seal the plate with a sealing film and incubate with shaking at 28°C for 1.5 h; After incubation, wash, add enzyme, substrate chromogenic solution and stop solution in sequence, and measure the OD value with an enzyme-linked immunosorbent assay (ELISA) reader within 30 min after the reaction stops.

[0088] Interleukins are a class of cytokines produced by various cells and acting on various cells, which are cytokines with important regulatory functions. They play an important role in transmitting information, activating and regulating immune cells, mediating the activation, proliferation and differentiation of T and B cells, and in inflammatory reactions. The results are as Figure 6 shown in Table 3, indicating that light causes an increase in the level of inflammation in the model mouse group, while both the low dose and high dose of Aronia melanocarpa fruit extract can significantly reduce the level of inflammation in vivo, suggesting that Aronia melanocarpa fruit extract has a protective effect on cell inflammatory reactions.

[0089] Although the above embodiments have described the present invention in detail, they are only a part of the embodiments of the present invention, not all of them. People can also obtain other embodiments based on these embodiments without creative efforts, and these embodiments all fall within the protection scope of the present invention.

Claims

1. Use of the composition of Aronia melanocarpa fruits in the preparation of eye care products.

2. The application according to claim 1, wherein The composition of Aronia melanocarpa fruits includes the extract of Aronia melanocarpa fruits or products made from the juice of Aronia melanocarpa fruits.

3. The application according to claim 2, wherein The extract of Aronia melanocarpa fruits includes the water extract of Aronia melanocarpa fruits obtained using water as a solvent; The products made from the juice of Aronia melanocarpa fruits include the juice powder prepared by juicing Aronia melanocarpa fruits.

4. The application according to claim 1, wherein The eye care products include at least one of the following functions: (1) Treating and / or preventing eye diseases related to retinal light damage; (2) Treating and / or relieving eye symptoms related to retinal light damage; (3) Relieving visual fatigue.

5. The application according to claim 1 or 4, characterized in that The types of the eye care products include at least one of the following categories: drugs, foods, and medical device products.

6. A drug related to the prevention and / or treatment of an eye disease associated with retinal light damage, characterized in that, Including active ingredients and pharmaceutically acceptable excipients; The active ingredients include the composition of Aronia melanocarpa fruits.

7. The drug according to claim 6, characterized in that, When the active ingredient of the drug includes the water extract of Aronia melanocarpa fruits, the working concentration of the water extract of Aronia melanocarpa fruits is not less than 87.5 μg / ml.

8. A health food for relieving visual fatigue, characterized in that, The active ingredients include the composition of Aronia melanocarpa fruits; The composition of Aronia melanocarpa fruits includes the extract of Aronia melanocarpa fruits or products made from the juice of Aronia melanocarpa fruits.

9. The health food according to claim 8, wherein The dosage forms of the health food include at least one of the following: ointments, powders, liquids, tablets, gels, capsules, and granules.

10. A general food containing the composition of Aronia melanocarpa fruits.

Images